These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 9759701

  • 1. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
    Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D'Eramo G, Di Nicola S, Toscano V.
    Prostate; 1998 Oct 01; 37(2):77-83. PubMed ID: 9759701
    [Abstract] [Full Text] [Related]

  • 2. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by treatment with finasteride or flutamide.
    Monti S, Sciarra F, Adamo MV, Toscano V, Trotta MC, Martini C, Lanzara S, Silverio FD.
    J Androl; 1997 Oct 01; 18(5):488-94. PubMed ID: 9349746
    [Abstract] [Full Text] [Related]

  • 3. Regional distribution of epidermal growth factor, testosterone and dihydrotestosterone in benign prostatic hyperplasia tissue.
    Sciarra F, Monti S, Adamo MV, Palma E, Toscano V, d'Eramo G, di Silverio F.
    Urol Res; 1995 Oct 01; 23(6):387-90. PubMed ID: 8788277
    [Abstract] [Full Text] [Related]

  • 4. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.
    Plosker GL, Brogden RN.
    Drugs Aging; 1996 Nov 01; 9(5):379-95. PubMed ID: 8922564
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.
    Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, Miñana López B, Fernández-Gómez JM, Angulo JC, Castro Díaz D, Romero-Otero J, Brenes FJ, Carballido J, Molero García JM, Fernández-Pro Ledesma A, Cózar Olmos JM, Manasanch Dalmau J, Subirana Cachinero I, Herdman M, Ficarra V.
    BJU Int; 2018 Dec 01; 122(6):1049-1065. PubMed ID: 29694707
    [Abstract] [Full Text] [Related]

  • 6. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
    Monti S, Di Silverio F, Iraci R, Martini C, Lanzara S, Falasca P, Poggi M, Stigliano A, Sciarra F, Toscano V.
    J Clin Endocrinol Metab; 2001 Apr 01; 86(4):1700-6. PubMed ID: 11297606
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride.
    Van Coppenolle F, Le Bourhis X, Carpentier F, Delaby G, Cousse H, Raynaud JP, Dupouy JP, Prevarskaya N.
    Prostate; 2000 Apr 01; 43(1):49-58. PubMed ID: 10725865
    [Abstract] [Full Text] [Related]

  • 8. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia.
    Vacherot F, Azzouz M, Gil-Diez-De-Medina S, Colombel M, De La Taille A, Lefrère Belda MA, Abbou CC, Raynaud JP, Chopin DK.
    Prostate; 2000 Nov 01; 45(3):259-66. PubMed ID: 11074529
    [Abstract] [Full Text] [Related]

  • 9. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.
    Buck AC.
    J Urol; 2004 Nov 01; 172(5 Pt 1):1792-9. PubMed ID: 15540722
    [Abstract] [Full Text] [Related]

  • 10. Serenoa repens extracts: In vitro study of the 5α-reductase activity in a co-culture model for Benign Prostatic Hyperplasia.
    Buonocore D, Verri M, Cattaneo L, Arnica S, Ghitti M, Dossena M.
    Arch Ital Urol Androl; 2018 Sep 30; 90(3):199-202. PubMed ID: 30362688
    [Abstract] [Full Text] [Related]

  • 11. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH.
    Bayne CW, Donnelly F, Ross M, Habib FK.
    Prostate; 1999 Sep 01; 40(4):232-41. PubMed ID: 10420151
    [Abstract] [Full Text] [Related]

  • 12. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.
    Habib FK, Ross M, Ho CK, Lyons V, Chapman K.
    Int J Cancer; 2005 Mar 20; 114(2):190-4. PubMed ID: 15543614
    [Abstract] [Full Text] [Related]

  • 13. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.
    Marks LS, Hess DL, Dorey FJ, Luz Macairan M, Cruz Santos PB, Tyler VE.
    Urology; 2001 May 20; 57(5):999-1005. PubMed ID: 11337315
    [Abstract] [Full Text] [Related]

  • 14. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
    Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP.
    Eur Urol; 2002 May 20; 41(5):497-506; discussion 506-7. PubMed ID: 12074791
    [Abstract] [Full Text] [Related]

  • 15. Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH).
    Monti S, Di Silverio F, Toscano V, Martini C, Lanzara S, Varasano PA, Sciarra F.
    J Androl; 1998 May 20; 19(4):428-33. PubMed ID: 9733145
    [Abstract] [Full Text] [Related]

  • 16. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.
    Boyle P, Robertson C, Lowe F, Roehrborn C.
    BJU Int; 2004 Apr 20; 93(6):751-6. PubMed ID: 15049985
    [Abstract] [Full Text] [Related]

  • 17. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
    Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P.
    Prostate; 1996 Oct 20; 29(4):231-40; discussion 241-2. PubMed ID: 8876706
    [Abstract] [Full Text] [Related]

  • 18. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].
    Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP, Groupe d'étude PERMAL.
    Prog Urol; 2002 Jun 20; 12(3):384-92; discussion 394-4. PubMed ID: 12189744
    [Abstract] [Full Text] [Related]

  • 19. A scientific basis for the therapeutic effects of Pygeum africanum and Serenoa repens.
    Levin RM, Das AK.
    Urol Res; 2000 Jun 20; 28(3):201-9. PubMed ID: 10929430
    [Abstract] [Full Text] [Related]

  • 20. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies.
    Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P.
    Eur Urol; 1998 Jun 20; 33(3):340-7. PubMed ID: 9555564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.